⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IBRX News
ImmunityBio, Inc. Common Stock
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
businesswire.com
IBRX
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
globenewswire.com
ONCY
IBRX
BNTX
CMPX
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA ® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
businesswire.com
IBRX
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA ® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
businesswire.com
IBRX
NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security
businesswire.com
IBRX
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
businesswire.com
IBRX
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
businesswire.com
IBRX
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA ® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
businesswire.com
IBRX
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
businesswire.com
IBRX
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
prnewswire.com
ONCY
ANIX
ICCM
IBRX
REGN
ONCY
ANIX
ICCM
IBRX
REGN